Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease

BACKGROUND AND AIMS: The current approach to managing the loss of response to anti-tumour necrosis factor (TNF) agents is generally empirical. Prior studies have suggested that adalimumab levels of >4.9 µg/mL are required to achieve clinical remission. Our aim was to identify an optimal adalimuma...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Crohns Colitis
Auteurs principaux: Zittan, E., Kabakchiev, B., Milgrom, R., Nguyen, G. C., Croitoru, K., Steinhart, A. H., Silverberg, M. S.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957459/
https://ncbi.nlm.nih.gov/pubmed/26783345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjw014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires